01.12.2016

AiCuris Announces Start of LipP 1
First Subject Enrolled in the Clinica Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

more ...

23.11.2016

AiCuris Announces U.S. NIH Support of Preclinical Study with AIC649

more ...

08.11.2016

AiCuris hosts mini-symposium of experts to discuss challenges and breakthroughs in anti-infectives at BIO-Europe® 2016

more ...

28.10.2016

AiCuris celebrates its 10th Anniversary hosting a Mini-Symposium on Challenges and Breakthroughs of Anti-infective Therapies at the BIO-Europe® 2016

more ...

19.10.2016

AiCuris’ licensee MSD says Letermovir, an investigational prophylactic therapy against HCMV in bone marrow transplant patients, met Primary Endpoint in Pivotal Phase 3 Study

more ...

27.09.2016

AiCuris with Case Study in Going Public “Biotechnologie 2016”

more ...

23.08.2016

AiCuris Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus, Achieves Primary Endpoint in Clinical Phase I Study

more ...

23.06.2016

Two Recent Publications on Pritelivir Confirm the Potency of the Novel AiCuris Anti-Herpes Simplex Virus Drug

more ...

04.04.2016

AiCuris Initiates Clinical Development for Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus

more ...

05.01.2016

AiCuris’ AIC649 Shows Potential to Induce Functional Cure of Chronic Hepatitis B in Preclinical Study

AIC649 is an inactivated parapoxvirus ovis (iPPVO) particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses. more ...